Clinical Trial

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Name: A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight — clinical trial record (NCT07710768)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

Trial Details

NCT Number	NCT07710768
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Overweight
Enrollment	44 participants
Start Date	2026-07-15
Primary Completion	2027-04-07 (estimated)
Study Completion	2027-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-17